Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Rahmi A, Mammar H, Thariat J, Angellier G, Herault J, Chauvel P, Kodjikian L, Denis P, Grange JD.

Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1515-21. doi: 10.1007/s00417-014-2735-y. Epub 2014 Jul 20.

PMID:
25038910
2.

Proton beam therapy for iris melanomas.

Lumbroso-Le Rouic L, Delacroix S, Dendale R, Levy-Gabriel C, Feuvret L, Noel G, Plancher C, Nauraye C, Garcia P, Calugaru V, Asselain B, Desjardins L.

Eye (Lond). 2006 Nov;20(11):1300-5. Epub 2006 Nov 18.

PMID:
16294207
3.

Proton beam radiotherapy of diffuse iris melanoma in 54 patients.

Willerding GD, Cordini D, Hackl C, Karle B, Lakotka N, Foerster MH, Bechrakis NN, Heufelder J, Moser L, Joussen AM.

Br J Ophthalmol. 2015 Jun;99(6):812-6. doi: 10.1136/bjophthalmol-2014-305174. Epub 2014 Dec 10.

PMID:
25505288
4.

Proton beam therapy for iris melanoma: a review of 15 cases.

Rundle P, Singh AD, Rennie I.

Eye (Lond). 2007 Jan;21(1):79-82. Epub 2006 Jan 13.

PMID:
16410818
5.

Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Riechardt AI, Karle B, Cordini D, Heufelder J, Budach V, Joussen AM, Gollrad J.

Strahlenther Onkol. 2017 Nov;193(11):943-950. doi: 10.1007/s00066-017-1166-1. Epub 2017 Jun 19.

PMID:
28631017
6.

Proton beam radiotherapy of iris melanoma.

Damato B, Kacperek A, Chopra M, Sheen MA, Campbell IR, Errington RD.

Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):109-15.

PMID:
16111578
7.

Recurrence of iris melanoma after proton beam therapy.

Sandinha MT, Kacperek A, Errington RD, Coupland SE, Damato B.

Br J Ophthalmol. 2014 Apr;98(4):484-7. doi: 10.1136/bjophthalmol-2013-303321. Epub 2014 Jan 10.

PMID:
24414401
8.

Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.

Riechardt AI, Klein JP, Cordini D, Heufelder J, Rehak M, Seibel I, Joussen AM.

Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1325-1332. doi: 10.1007/s00417-018-3929-5. Epub 2018 Feb 20.

PMID:
29464331
9.

Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.

Riechardt AI, Pilger D, Cordini D, Seibel I, Gundlach E, Hager A, Joussen AM.

Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2263-2269. doi: 10.1007/s00417-017-3737-3. Epub 2017 Jul 18.

PMID:
28721444
10.

Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.

Shields CL, Shah SU, Bianciotto CG, Emrich J, Komarnicky L, Shields JA.

Ophthalmology. 2013 Jan;120(1):55-61. doi: 10.1016/j.ophtha.2012.06.053. Epub 2012 Sep 12.

PMID:
22980742
11.

Ruthenium plaque radiation therapy for iris and iridociliary melanomas.

Razzaq L, Keunen JE, Schalij-Delfos NE, Creutzberg CL, Ketelaars M, de Keizer RJ.

Acta Ophthalmol. 2012 May;90(3):291-6. doi: 10.1111/j.1755-3768.2010.01967.x. Epub 2010 Jul 29.

12.

Conservative management of suspicious melanocytic lesions of the iris.

Oxenreiter MM, Lane AM, Jain P, Kim IK, Gragoudas ES.

Graefes Arch Clin Exp Ophthalmol. 2019 Jun;257(6):1319-1324. doi: 10.1007/s00417-019-04296-0. Epub 2019 Mar 27.

PMID:
30919077
13.

Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases.

Shah SU, Shields CL, Bianciotto C, Emrich J, Komarnicky L, Shields JA.

Ophthalmology. 2012 Apr;119(4):838-842.e2. doi: 10.1016/j.ophtha.2011.09.039. Epub 2011 Nov 30.

PMID:
22133794
14.

Whole anterior segment proton beam radiotherapy for diffuse iris melanoma.

Konstantinidis L, Roberts D, Errington RD, Kacperek A, Damato B.

Br J Ophthalmol. 2013 Apr;97(4):471-4. doi: 10.1136/bjophthalmol-2012-302659. Epub 2013 Jan 7.

PMID:
23298884
15.

Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique.

Hartsell WF, Kapur R, Hartsell SO, Sweeney P, Lopes C, Duggal A, Cohen J, Chang J, Polasani RS, Dunn M, Pankuch M.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):353-9. doi: 10.1016/j.ijrobp.2016.02.039. Epub 2016 Feb 16.

PMID:
27084652
16.

Plaque radiation therapy for malignant melanoma of the iris and ciliary body.

Finger PT.

Am J Ophthalmol. 2001 Sep;132(3):328-35.

PMID:
11530044
17.

Genetic findings in treatment-naïve and proton-beam-radiated iris melanomas.

Krishna Y, Kalirai H, Thornton S, Damato BE, Heimann H, Coupland SE.

Br J Ophthalmol. 2016 Jul;100(7):1012-1016. doi: 10.1136/bjophthalmol-2015-308301. Epub 2016 Apr 20.

PMID:
27098748
18.

Proton beam therapy leads to excellent local control rates in choroidal melanoma in the intermediate fundus zone.

Schönfeld S, Cordini D, Riechardt AI, Seibel I, Willerding G, Bechrakis NE, Moser L, Joussen AM.

Am J Ophthalmol. 2014 Dec;158(6):1184-91. doi: 10.1016/j.ajo.2014.08.016. Epub 2014 Aug 13.

PMID:
25128597
19.

Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications.

Shields CL, Naseripour M, Shields JA, Freire J, Cater J.

Am J Ophthalmol. 2003 May;135(5):648-56.

PMID:
12719072
20.

Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.

Yousef YA, Finger PT.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1107-12. doi: 10.1016/j.ijrobp.2011.09.033. Epub 2011 Dec 13.

PMID:
22172910

Supplemental Content

Support Center